blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3010526

EP3010526 - USE OF A VEGF ANTAGONIST IN TREATING MACULAR EDEMA [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.04.2018
Database last updated on 19.10.2024
FormerRequest for examination was made
Status updated on  24.01.2018
Most recent event   Tooltip27.04.2018Application deemed to be withdrawnpublished on 30.05.2018  [2018/22]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2016/17]
Inventor(s)01 / BURIAN, Gabriela
c/o Novartis Pharma AG
Postfach
CH-4002 Basel / CH
 [2016/17]
Representative(s)Stierwald, Michael
Novartis Pharma AG
Patent Department
Forum 1
Novartis Campus
4056 Basel / CH
[2016/17]
Application number, filing date14733731.518.06.2014
[2016/17]
WO2014IB62372
Priority number, dateUS201361837253P20.06.2013         Original published format: US 201361837253 P
[2016/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014203183
Date:24.12.2014
Language:EN
[2014/52]
Type: A1 Application with search report 
No.:EP3010526
Date:27.04.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 24.12.2014 takes the place of the publication of the European patent application.
[2016/17]
Search report(s)International search report - published on:EP24.12.2014
ClassificationIPC:A61K38/17, A61K39/395, A61K47/48, A61P27/02
[2016/17]
CPC:
A61K38/179 (EP,US); C07K14/71 (US); A61K39/3955 (US);
A61K45/06 (US); A61P27/02 (EP); C07K2319/30 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/17]
TitleGerman:VERWENDUNG EINES VEGF-ANTAGONISTEN IN BEHANDLUNG VON MAKULAÖDEMEN[2016/17]
English:USE OF A VEGF ANTAGONIST IN TREATING MACULAR EDEMA[2016/17]
French:UTILISATION D'UN ANTAGONISTE DU VEGF DANS LE TRAITEMENT D'UN DÈME MACULAIRE[2016/17]
Entry into regional phase18.12.2015National basic fee paid 
18.12.2015Designation fee(s) paid 
18.12.2015Examination fee paid 
Examination procedure18.12.2015Amendment by applicant (claims and/or description)
18.12.2015Examination requested  [2016/17]
03.01.2018Application deemed to be withdrawn, date of legal effect  [2018/22]
25.01.2018Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2018/22]
Fees paidRenewal fee
10.06.2016Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
30.06.201704   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[YP]WO2014033184  (NOVARTIS AG [CH], et al) [YP] 1-22* page 5, lines 6-11 *;
 [XY]  - JEFFREY S. HEIER ET AL, "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", OPHTHALMOLOGY, (20121201), vol. 119, no. 12, doi:10.1016/j.ophtha.2012.09.006, ISSN 0161-6420, pages 2537 - 2548, XP055138976 [X] 1,6,9-12,16,17,21 * the whole document * [Y] 2-5,7,8,13-15,18-20,22

DOI:   http://dx.doi.org/10.1016/j.ophtha.2012.09.006
 [XI]  - JAMROZY-WITKOWSKA AGNIESZKA ET AL, "[Complications of intravitreal injections--own experience]", KLINIKA OCZNA - ACTA OPHTHALMOLOGICA POLONICA, WARSZAWA, PL, (20110101), vol. 113, no. 4-6, ISSN 0023-2157, pages 127 - 131, XP009180095 [X] 1 * abstract * [I] 2-22
 [I]  - FINE HOWARD F ET AL, "Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema", AMERICAN JOURNAL OF OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, (20011101), vol. 132, no. 5, doi:10.1016/S0002-9394(01)01103-5, ISSN 0002-9394, pages 794 - 796, XP002253499 [I] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0002-9394(01)01103-5
 [I]  - WIEGAND S J ET AL, "LONG - LASTING INHIBITION OF CORNEAL NEOVASCULARIZATION FOLLOWING SYSTEMIC ADMINISTRATION OF THE VEGF TRAP", BIOSIS,, (20030101), Database accession no. PREV200300511706, URL: BIOSIS, XP002716541 [I] 1,10,11 * abstract *
 [I]  - KENICHI KIMOTO ET AL, "Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability", JOURNAL OF OPHTHALMOLOGY, (20120101), vol. 19, no. 14, doi:10.1001/archophthalmol.2008.1, ISSN 2090-004X, pages 5731 - 11, XP055141705 [I] 1-22 * page 1, column l, paragraph 1 - column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1155/2012/852183
 [Y]  - BAE J H ET AL, "Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema", RETINA, LIPPINCOTT WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, (20110101), vol. 31, no. 1, doi:10.1097/IAE.0B013E3181E378AF, ISSN 0275-004X, pages 111 - 118, XP009180094 [Y] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1097/IAE.0b013e3181e378af
 [Y]  - CERVANTES-CASTA PRG NEDA RENE A ET AL, "Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up", EUROPEAN JOURNAL OF OPHTHALMOLOGY, MILAN, IT, (20090701), vol. 19, no. 4, ISSN 1120-6721, pages 622 - 629, XP009180093 [Y] 1-22 * the whole document *
 [Y]  - K WEISS ET AL, "Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab", EYE, (20090901), vol. 23, no. 9, doi:10.1038/eye.2008.388, ISSN 0950-222X, pages 1812 - 1818, XP055141699 [Y] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1038/eye.2008.388
 [Y]  - DIANA V DO ET AL, "The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 118, no. 9, doi:10.1016/J.OPHTHA.2011.02.018, ISSN 0161-6420, (20110209), pages 1819 - 1826, (20110214), XP028281066 [Y] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ophtha.2011.02.018
 [Y]  - DAVID BOYER ET AL, "Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 119, no. 5, doi:10.1016/J.OPHTHA.2012.01.042, ISSN 0161-6420, (20120120), pages 1024 - 1032, (20120125), XP028422356 [Y] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ophtha.2012.01.042
 [Y]  - LI T ET AL, "KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization", MOLECULAR VISION, MOLECULAR VISION, SN, ATLANTA, (20110325), vol. 17, no. 89-90, ISSN 1090-0535, pages 797 - 803, XP002716540 [Y] 1-22 * the whole document *
 [Y]  - KIM EUGENE S ET AL, "Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (20020820), vol. 99, no. 17, doi:10.1073/PNAS.172398399, ISSN 0027-8424, pages 11399 - 11404, XP002391853 [Y] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.172398399
 [Y]  - HOLASH JOCELYN ET AL, "VEGF-Trap: A VEGF blocker with potent antitumor effects", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (20020820), vol. 99, no. 17, doi:10.1073/PNAS.172398299, ISSN 0027-8424, pages 11393 - 11398, XP002300698 [Y] 1-22 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.172398299
 [Y]  - YANOFF M ET AL, "Pathology of human cystoid macular edema", SURVEY OF OPHTHALMOLOGY, SURVEY OF OPHTHALMOLOGY INC, XX, vol. 28, doi:10.1016/0039-6257(84)90233-9, ISSN 0039-6257, (19840501), pages 505 - 511, (19840501), XP023265836 [Y] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1016/0039-6257(84)90233-9
by applicantWO02100318
 US2005281861
 EP1767546
 US2008107694
 WO2010060748
 WO2010088548
 WO2011135067
    - YANOFF ET AL., SURV OPHTHALMOL., (1984), vol. 28, pages 505 - 1 1
    - FINE ET AL., AM J OPHTHALMOL., (2001), vol. 132, no. 5, pages 794 - 6
    - WEISS ET AL., EYE (LOND)., (2009), vol. 23, no. 9, pages 1812 - 8
    - BAE ET AL., RETINA, (2011), vol. 31, no. 1, pages 111 - 8
    - CERVANTES-CASTANEDA ET AL., EUR J OPHTHALMOL., (2009), vol. 19, no. 4, pages 622 - 9
    - KOK, OPHTHALMOLOGY, (2005), vol. 112, no. 11, pages 1916.EL - 7
    - BARKMEIER; AKDUMAN, OCUL IMMUNOL INFLAMM, (2009), vol. 17, no. 2, pages 109 - 17
    - BUCHHOLZ ET AL., DEV OPHTHALMOL., (2010), vol. 46, pages 111 - 22
    - BARKMEIER; AKDUMAN, OCUL IMMUNOL INFLAMM., (2009), vol. 17, no. 2, pages 109 - 17
    - HOLASH ET AL., PNAS USA, (2002), vol. 99, pages 11393 - 98
    - RIELY; MILLER, CLIN CANCER RES, (2007), vol. 13, pages 4623 - 7S
    - LI ET AL., MOLECULAR VISION, (2011), vol. 17, pages 797 - 803
    - DAYHOFF ET AL., Atlas of Protein Sequence and Structure, (1978), vol. 5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.